Clinical Research Papers:
The preoperative sensitive-modified Glasgow prognostic score is superior to the modified Glasgow prognostic score in predicting long-term survival for esophageal squamous cell carcinoma
Metrics: PDF 1433 views | HTML 1849 views | ?
Rui Tian1, Fei Zhang2,3,4, Peng Sun2,3,4, Jing Wu1, Hong Yan1, Ai-Ran Wu1, Min Zhang1, Yu-Lu Jiang1, Yan-Hong Lu5, Qiu-Yan Xu1, Xiao-Hong Zhan1, Rong-Xin Zhang5, Li-Ting Qian6 and Jie He1
1 Department of Pathology, Anhui Cancer Hospital & Anhui Provincial Hospital Affiliated Anhui Medical University, Hefei, Anhui, People’s Republic of China
2 Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, People’s Republic of China
3 State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, People’s Republic of China
4 Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, People’s Republic of China
5 Department of Thoracic Surgery, Anhui Cancer Hospital & Anhui Provincial Hospital Affiliated Anhui Medical University, Hefei, Anhui, People’s Republic of China
6 Department of Radiology, Anhui Provincial Hospital & Anhui Provincial Hospital Affiliated Anhui Medical University, Hefei, Anhui, People’s Republic of China
Li-Ting Qian, email:
Jie He, email:
Keywords: esophageal squamous cell carcinoma; modified Glasgow prognostic score; superiority; survival
Received: June 07, 2016 Accepted: July 30, 2016 Published: August 12, 2016
The present study was designed to investigate the prognostic significance of the preoperative sensitive-modified Glasgow prognostic score (S-mGPS) and its superiority in esophageal squamous cell carcinoma (ESCC). Clinicopathologic characteristics, preoperative albumin and C-reactive protein (CRP) levels were retrospectively collected in 442 patients who underwent transthoracic esophagectomy. The S-mGPS was calculated before surgery based on optimal cutoff values of 45.6 g/L for albumin and 10.0 mg/L for CRP. 360, 74 and 8 cases were assigned an mGPS of 0, 1 and 2, respectively. In contrast, the S-mGPS was 0 in 114, 1 in 258 and 2 in 70 patients. Of the 360 patients with an mGPS of 0, 246 migrated to the S-mGPS-1 group. Both mGPS and S-mGPS were significantly correlated with tumor length, depth of invasion, pathological tumor-node-metastasis (pTNM) stage and adjuvant treatment. In addition, they were significantly associated with disease free survival (DFS) and overall survival (OS) in univariate analysis. Furthermore, multivariate Cox regression analysis identified S-mGPS as an independent prognostic indicator for both DFS [hazard ratio (HR), 1.577; 95% confidence interval (CI), 1.149-2.163; P = 0.005] and OS (HR, 1.762; 95% CI, 1.250-2.484; P = 0.001), but not mGPS (HR, 0.957; 95% CI, 0.692-1.323; P = 0.790 for DFS and HR, 1.089; 95% CI, 0.781-1.517; P = 0.615 for OS, respectively). Moreover, subgroup analysis revealed that the prognostic impact of the S-mGPS was especially striking in pTNM stage II patients. The preoperative S-mGPS is superior to the mGPS as a prognostic predictor in patients with resectable ESCC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.